Teva Pharmaceutical Industries Ltd. announced today that additional data analyzed from the Phase III clinical program for QNASL ® (beclomethasone dipropionate) Nasal Aerosol will be presented at the 2013 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) in San Antonio, Texas on February 22-26, 2013. QNASL ® is a nonaqueous or “dry-mist” nasal aerosol corticosteroid that treats seasonal and year-round nasal allergy symptoms in adults and adolescents 12 years of age and older.
Data will be presented at the meeting regarding the efficacy of QNASL ® in treating the symptoms associated with seasonal and perennial allergic rhinitis (SAR and PAR), including the drug’s potential quality of life benefits and sleep quality improvement. Furthermore, the data also demonstrated nasal symptom relief in patients with SAR and PAR who received treatment with QNASL ® 24 hours after dosing.
On March 23, 2012, the U.S. Food and Drug Administration (FDA) approved QNASL ®. The product became available by prescription in April 2012, making it the first marketed nonaqueous or “dry-mist” nasal aerosol product in a category that reports annual sales of $2.5 billion. QNASL ® is delivered as a once-daily, nonaqueous aerosol that uses an environmentally friendly propellant (HFA) and contains a built-in dose counter.
“These studies are important because the impact of allergic rhinitis on a patient’s quality of life is significant. Nasal allergies are often associated with burdensome symptoms such as nasal congestion, sneezing, and itchy and runny nose, which may contribute to disrupted sleep and impaired daytime activities,” said Dr. Eli Meltzer, Senior Associate, Allergy & Asthma Medical and Research Center, A.P.C. and Clinical Professor, Department of Pediatrics, Division of Allergy and Immunology, University of California, San Diego. “These findings reinforce the efficacy of QNASL ® to treat nasal symptoms and to provide sustained relief from burden of allergic rhinitis.”The following QNASL ® data will be presented during poster sessions on Sunday, February 24 from 9:45 – 10:45 a.m. (CST) in Hall C (street level) of the Henry B. Gonzalez Convention Center at the AAAAI Annual Meeting:
- #P409: Improvement of Nasal Congestion and Sleep Quality Following Once-Daily Treatment with Beclomethasone Dipropionate Nasal Aerosol in Patients with Seasonal Allergic Rhinitis
- #P413: Once-Daily Treatment with Beclomethasone Dipropionate Nasal Aerosol Provides Long-Term and Sustained 24-Hour Nasal Symptom Relief in Patients with Perennial Allergic Rhinitis
- #P414: Once-Daily Treatment with Beclomethasone Dipropionate Nasal Aerosol Effectively Improves the Symptom of Itchy Ear or Palate Associated with Seasonal Allergic Rhinitis
- #P415: Once-Daily Treatment with Beclomethasone Dipropionate Nasal Aerosol 320 mg Provides 24-Hour Nasal Symptom Relief in Patients with Seasonal Allergic Rhinitis
- #P144: QNASL ® (beclomethasone dipropionate) Nonaqueous Nasal Aerosol Delivers Softer Sprays Than Aqueous Flonase ®, Nasacort AQ ®, and Nasonex ®
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV